# New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy

> **NCT04564157** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Fundación GECP** · enrollment: 210 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Adjuvant Chemotherapy

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04564157
- **Lead sponsor:** Fundación GECP
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-01-13
- **Primary completion:** 2030-04-01
- **Final completion:** 2031-04-01
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04564157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04564157, "New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04564157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*